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Abstract  
Introduction: Parkes Weber Syndrome (PWS) is a traditional eponymous denomination of a 
certain type of angiodysplasia. It is a congenital vascular disease which consists of capillary 
malformation (CM), venous malformation (VM), lymphatic malformation (LM), congenital 
arteriovenous malformation (AVM) and multiple arteriovenous fistulas (AVFs). There is a 
soft-tissue and skeletal hypertrophy of the affected extremity (usually a lower extremity). 
Moreover the affected limb is warmer and longer than the other side. 
Objective: The aim of this article is to summarize the current state of knowledge about 
Parkes Weber Syndrome: the pathophysiology, genetic inheritance, the main symptoms, the  
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diagnosis especially differential diagnosis and the current treatment. 
Brief descriptions of the state of knowledge: Despite many years, physicians still have 
difficulties with diagnosing PWS correctly. Although the aetiology is unknown, it is claimed 
that PWS is caused by mutations of the RASA1, gene located on chromosome 5q13.1, which 
are inherited in an autosomal dominant manner. This gene is responsible for mediating 
cellular growth, differentiation and proliferation. No efficacious pharmacological treatment 
has been found. Nowadays Tranexamic Acid, Sirolimus, Everolimus and Miconazole are 
used in medical practice. The most frequently utilized invasive treatment methods are 
amputation, surgical AVM resection and occasionally stent-graft implantation. Furthermore 
it is thought that embolization, alone or combined with surgical resection leads to clinical 
improvement. 
Summary: Despite the existence of many clinical trials, long term observations and 
scientific speculations, PWS can still be challenging  for clinicians. There is a need for 
further scientific, molecular and genetic research to diagnose this phenomenon correctly, 
because despite fact, that its symptoms are similar to other syndromes or entities, therapeutic 
strategies differ significantly. It is important to increase the awareness of inheritance in an 
autosomal dominant manner in generation of patients with PWS. 
 
Keywords: Parkes Weber syndrome, PWS, Klippel-Trenaunay syndrome, congenital 
vascular malformation, arteriovenous malformation 
 
 
 
Introduction 
Parkes-Weber syndrome is defined by the presence of a capillary vascular malformation with 
high-flow arteriovenous malformation and multiple arteriovenous fistulas (AVFs) in 
association with soft-tissue and skeletal hypertrophy of the affected extremity (usually a lower 
extremity). [1,3,5] Moreover the affected extremity is warmer and longer than the second one, 
a bruit or thrill may also be detected. [3,6] Incidence is unknown but men and women are 
affected equally. [3] It is claimed that PWS is caused by mutations of the RASA1, gene on 
chromosome 5q13.1, which are inherited in an autosomal dominant manner. This gene is 
responsible for mediating cellular growth, differentiation and proliferation (through the 
tyrosine kinase pathway). [2,4,6] Although PWS is a clinically distinctive entity, it is still 
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frequently misdiagnosed as Klippel–Trenaunay syndrome (KTS). Moreover both Parkes 
Weber and KTS have CM, VM, LM but PWS has in addition AVM, which is very substantial 
during planning a treatment strategy. [1,3,4,5] The prognosis of PWS is more problematic 
than in KTS. The main complications and the most dangerous are heart failure, cardiac 
enlargement, cutaneous ischemia and limb amputation. [1,2] 
The main concept of the treatment is to slow: the progression of PWS, heart failure, limb 
hypertrophy and development of varicose veins as soon as practically possible. Unfortunately, 
no efficacious pharmacological treatment has been found. What is more, the use of 
compression garments (e.g. compression stockings) can reduce oedema, improve increasing 
blood flow and minimalize pain and swelling. [1,4,6] The current results show that the most 
frequently utilized invasive treatments are amputation, surgical AVM resection and 
occasionally stent-graft implantation. Furthermore, it is thought that embolization, alone or 
combined with surgical resection leads to clinical improvement. [1] 
 
History 
Parkes Weber syndrome (PWS) was first described by Frederick Parkes Weber in 1907. 
Parkes Weber described patients with capill venous malformations or ary enlargement of a 
limb, enlarged veins and arteries in numerous scientific articles. Research conducted by 
Eerola et al. in 2002 and 2003 proved that Parkes Weber syndrome is a family disease. In 
addition, this fact was confirmed by research carried out by Revencu et al. in 2008. They 
demonstrated that this phenomenon is caused by RASA1 gene mutations, as well as many 
fast-flow vascular malformations. [2] 
 
Epidemiology 
Numerous studies prove that the cause of the disease is a genetic mutation. In addition, the 
mutation can be inherited or may arise de novo [7]. About 70% of affected of PWS 
individuals have an affected parent, while about 30% have a de novo pathogenic variant. 
Numerous studies prove that RASA1-related disorders are inherited in an autosomal dominant 
manner. In this connection each child with a mutation in RASA-1 has 50% risk of inheriting 
the pathogenic variant. Nevertheless, genetic diagnosis before implantation is possible, as 
well as prenatal diagnosis for pregnant women. If the pathogenic version of RASA1 has been 
recognized in an affected family member. Limb hyperplasia has been reported in both lower 
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and upper limbs in RASA1-related disorders. Hypertrophy is usually noticeable in infancy. 
What is more observations shows that this process can have varying level of severity. [8] 
Moreover, detailed diagnosis is clinically important, because patients with Parkes Weber 
syndrome are at risk of cardiac overload, ulceration, and even cardiac failure. [7] 
 
The table 1 contains data for Parkes Weber syndrome until 2016. 36 publications were 
included, including 48 patients. [1] 
Table 1 
Patients characteristics Numerical data 
The median age of patients 23 years (IQR, 8–32) 
PWS and high-output heart failure 31.3% 
Gender predominance female-male ratio: 50%:50% 
Chronic venous ulcerations of the affected limb 25.0% 
Distal arterial ischemia 8.3% 
Lower extremity was affected 87.5% 
Upper extremity was affected 12.5% 
Spinal arteriovenous malformations 12.5% 
Coexistence of aneurysmatic disease            10.4% 
 
Etiology and pathophysiology 
Pathophysiology has not been well established and the mechanisms of pathogenesis are also 
unclear, although there are many theories described in the literature, such as congenital 
obstruction of the deep veins pertaining to the involved limb [9], mesodermal anomalies 
resulting in poor formation of vascular and soft tissues during fetal period and finally 
mutations of genes that determine growth and cellular differentiation, combined with defects 
of the 5q chromosome (CMC1 locus), which is vital to angiogenesis. [2] There are also newer 
studies that show that PWS is caused by mutations of the RASA1 gene. The RASA1 gene 
encodes the p120-RasGAP protein. It is responsible for promoting signaling for varied growth 
factor receptors that control migration, proliferation and survival of respective cell types, 
including vascular endothelial cells. [2] In patients with Parkes Weber syndrome were 
identified the heterozygous loss-of-function RASA1 mutations. Mutations in the RASA1 gene 
induce production of  nonfunctional version of the p120-RasGAP protein. This results in 
formation of arteriovenous micro fistulas, capillary blush on extremity and bony and soft 
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tissue hypertrophy. Parkes Weber syndrome has been shown to cover the phenotypic 
spectrum of capillary malformations - an arteriovenous defect. 
 
Symptoms 
PWS usually affects a single extremity, although multiple locations have been described. 
Most of the patients have lower limb involvement. Early clinical signs include a geographic 
stain over a limb. In addition, the skin may appear hyperpigmented and varicose veins or even 
microcystic lymphatic malformations may be present. It is important to note that limb 
hypertrophy is associated with longitudinal growth, which is a sign of bone involvement and 
on the other hand, peripheral growth as a sign of soft tissue involvement. Patients with AVFs 
have a greater degree of hypertrophy. Sciatic nerve enlargement, optic nerve variant, 
vesicoureteral reflux, colonic involvement and hemimegalencephaly associated with PWS 
have been described. [11-15]  AVFs are the clinical hallmark of PWS. The affected extremity 
is warmer and longer than the other one, and a bruit or thrill may be explored. Digital closure 
of an artery proximal to an AVF may lead to bradycardia. This phenomenon is called 
Branham’s sign and it may be present in PWS. Cardiac changes include compensatory 
tachycardia, increased blood pressure and hypertrophy of the right and then left cardiac 
chambers. The hypertrophy occurs as a result of hyperkinetic circulation. The degree of 
hypertrophy depends on the size and number of AVFs, resulting in lymphedema, distal skin 
alterations secondary to ischemic steal syndrome, and pain, all of which start during 
childhood. Ulceration associated with AVMs is secondary to blood steal by the hyperactive 
AVM nidus. Venous dilatation in PWS patients is secondary to epherent hyperflow from the 
nidus and not secondary to venous valve incompetence. The deformity tends to progress 
slowly over time, showing a significant longitudinal growth, until the epiphysis is closed. 
However, pain and fatigue are the most common clinical manifestations. PWS is associated 
with pulmonary manifestations such as thromboembolic phenomena, pulmonary venous 
varicosities and pulmonary lymphatic obstruction. [1] In the literature there are also reports 
about rare cases with hydronephrosis and Kasabach-Merritt coagulopathy. [16] 
 
Diagnosis 
Diagnosis of the Parkes Weber syndrome is usually based on clinical symptoms. [1,2,6,8,17] 
A combination of a cutaneous capillary–lymphatic-VM with AVMs (as main defect) defines 
the syndrome. Ankle–brachial index assessment should compliment physical examination of 
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the lower extremity because of the distal arterial ischemia of the affected limb. [1] Imaging 
techniques are necessary to reveal type, location and extent of the AV lesions. The gold 
standard is contrast arteriography. [5]  It is usually reserved for patients who are potential 
candidates for embolization. [1,5] Digital Subtraction Angiography (DSA)  is the gold 
standard for the precise separation of high-flow and low-flow vascular malformations. [5] 
Rapid contrast opacification of the draining veins is typically seen on all angiographic 
imaging examinations. [2] Magnetic resonance imaging (MRI) is the basis for imaging 
overgrowth syndromes involving the limbs. MRI is important to assess the deep lymphatic, 
venous and adipose components in the affected extremity. [2] In MR imaging of high-flow 
vascular malformations, the main feature on spin-echo sequences are flow-voids. [5] On MRI 
(T1 and T2 weighted images), signal voids are seen in the vessels with a high flow - arteries, 
arteriovenous shunts and other veins depending on the degree of the blood flow. [2] In T2 
weighted and post gadolinium sequences often show irregular increased signal in some of the 
muscles. They may have local arteriovenous (AV) shunts, increased subcutaneous fat and 
lymphedema. [2] The results present that MRPA (MR projection angiography) may detect 
arteriovenous shunting non-invasively and this distinguish Parkes Weber from Klippel-
Trenaunay syndrome. Grey scale and Doppler US are non-invasive methods to distinguish 
extracranial high-flow from low-flow vascular malformations. [5] On the basis of the results 
of imaging examinations, treatment is planned. [1] 
Parkes Weber syndrome is caused by RASA1 gene mutations. First the analysis of the 
sequence of  RASA-1 is performed. Detected variants are benign, likely benign, of uncertain 
significance, likely pathogenic  or pathogenic. Pathogenic variants may include small 
intragenic deletions/insertions and missense, nonsense, and splice site variants. Typically, 
exon or whole-gene deletions/duplications are not detected. Then gene-targeted 
deletion/duplication analysis detects intragenic deletions or duplications. Methods used 
include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification 
(MLPA) and a gene-targeted microarray designed to detect single-exon deletions or 
duplications. [8] 
 
The clinical manifestations of RASA1-related disorders [8] 
• Capillary Malformations (CM) 
• Arteriovenous Malformations / Arteriovenous Fistulas (AVMs/AVFs) 
• Parkes Weber syndrome 
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• Cardiac overload/failure 
• Lymphatic malformations 
• Tumors (e.g., optic glioma, lipoma, superficial basal cell carcinoma, angiolipoma, 
nonsmall-cell lung cancer, and vestibular schwannoma) 
Table 2 Disorders to Consider in the Differential Diagnosis of RASA1-Related Disorders [8]  
Disorder Gene(s) 
Hereditary hemorrhagic telangiectasia 
ACVRL 
ENG 
GDF2 
SMAD 
Sturge Weber syndrome GNAQ 
Klippel-Trenaunay-Weber syndrome PIK3CA 
PTEN hamartoma tumore syndrome PTEN 
Multiple cutaneous and mucosal venous 
malformations 
TEK 
Hereditary glomuvenous malformations 
(GVM) 
GLMN 
Hereditary benign telangiectasia Unknown 
 
Differential diagnosis of Parkes Weber syndrome: [2]  
• Klippel–Trenaunay syndrome,  
• extensive infantile hemangioma with arteriovenous shunting,  
• rapidly involuting congenital hemangioma (RICH) 
• noninvoluting congenital hemangioma (NICH) 
• Proteus sydrome 
 
Parkes Weber syndrome is often misdiagnosed as Klippel–Trenaunay syndrome. The main 
differences between syndromes are presented in Table 2.  
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Table 3 Comparison of Klippel–Trenaunay syndrome and Parkes Weber syndrome [2,5,18] 
 Klippel–Trenaunay syndrome Parkes Weber syndrome 
Types of vascular 
malformation 
Slow flow 
capillary, lymphatic, venous 
Fast flow 
capillary, arterial, venous 
Colour of cutaneous 
malformation 
Bluish to purplish, localized Pinkish to red, diffuse 
Arteriovenous fistulas Insignificant Significant 
Lateral venous anomaly Very common Not found 
Venous flares Present Not found 
Lymphatic vesicle Present Not found 
Limb involved 
Upper 
Lower 
 
5% 
95% 
 
23% 
77% 
Limb enlargement 
Usually disproportionate 
Soft tissues, bone 
Macrodactyly (toes),common 
arm/leg length discrepancy 
Prognosis 
Usually good 
Pulmonary embolism (10% 
children) 
Postoperative risk of embolism 
More problematic (fistulas) 
Heart failure 
Cardiac enlargement 
Cutaneous ischemia 
Limb amputation 
Bone alteration 
Rarefied, 
osteoporosis 
Rarefied, 
osteoporosis 
Brain involvement Not reported Intracranial AVM or AVF 
Spinal vascular disorders None 
Extradural and spinal  
AVM 
Involved gene mutation AGGF1, PIK3CA RASA1 
 
Treatment 
There is no effective pharmacotherapy yet. The primary goal should be to improve the quality 
of patient’s  life and reduce the risk of complications . The treatment is symptomatic and 
should be individualized according to the age and clinical features. [6] The most common 
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invasive treatment methods are: embotherapy followed by amputation and surgical AVM 
resection. Occasionally stent-graft implantation can be performed. 
 
The absolute indications for invasive treatment of vascular malformation include: [1] 
• hemorrhage, 
• distal ischemia, 
• refractory ulcers, 
• high-output heart failure. 
 
Relative indications for invasive treatment include: [1] 
• chronic pain, 
• claudication, 
• functional impairment, 
• limb asymmetry, 
• cosmetic reasons. 
 
Embolization is the most commonly used procedure in patients with PWS leading to clinical 
improvement of the limb pain and ischemia, high-output heart failure, myelopathy (related to 
concomitant spinal AVM) and nonsurgical patients with multiple and deep arteriovenous 
fistulae. [1,6] Most patients may need a multiple embolization session. [2] Extremity 
amputation may happen due to distal arterial ischemia, high-output heart failure. [1]  Patients 
with high-output heart failure, recurrent venous ulcerations, chronic pain and arterial 
aneurysm can be treated by surgical AVM resection. Surgical resection can also be combined 
with preoperative embolization, minimizing bleeding during surgery. [1] Compression 
stockings can be helpful to reduce edema and to improve  blood flow in order to heal venous 
ulcerations. [1] Compression garment therapy can be started at 3 months of age. [6] 
 
Summary 
Diagnosing a rare and genetic disease is often very challenging. Patients with Parkes Weber 
syndrome need multidisciplinary medical care. They need the consultations from 
dermatologists, general surgeons, plastic surgeons, vascular surgeons, orthopedists, 
interventional radiologists, cardiologists. The prognosis is very problematic and depends on 
clinical symptoms, numbers of complications and treatment used. 
996 
 
References 
1. Banzic I., Brankovic M., Maksimovic Z.; Parkes Weber syndrome—Diagnostic and 
management paradigms: A systematic review. Sage journals, Phlebology, 2016 
2. Konez O., Ruggieri M., Rocco C.D. (2008) Parkes Weber Syndrome. In: Ruggieri M., 
Pascual-Castroviejo I., Di Rocco C. (eds) Neurocutaneous Disorders Phakomatoses and 
Hamartoneoplastic Syndromes. Springer, Vienna 
3. Ferrero E., Ferri M., Viazzo A. Parkes-Weber Syndrome and Giant Superficial Femoral 
Artery Aneurysm. Treatment by Endovascular Therapyand Follow-Up of 8 Years. Annals of 
Vascular Surgery,2010;  25: 384.e9-384.e15 
4. Carlos Alberto Araujo Chagas, Lucas Alves SarmentoPires et al.Klippel-Trenaunay and 
Parkes-Weber syndromes: two case reports. J Vasc Bras. 2017 Out.-Dez.; 16(4):320-324 
5. S. Ziyeh S., Spreer J.,  Rössler J. Parkes Weber or Klippel-Trenaunay syndrome? Non-
invasive diagnosis with MR projection Angiography. Springer-Verlag. EurRadiol (2004) 
14:2025–2029 
6. Giron-Vallejo O.,Lopez-Gutierrez J.C., Fernandez-Pineda I.,Diagnosis and Treatment of 
Parkes Weber Syndrome: A Review of 10 Consecutive Patients; Annals Vascular Surgery – 
Journal 2013; 27: 820–825 
7. Revencu N., Boon L.M., Dompmartin A., Rieu P., Busch W.L., Dubois J., Forzano F., van 
Hagen J.M., Halbach S., Kuechler A., Lachmeijer A.M., Lähde J., Russell L., Simola K.O., 
Mulliken J.B., Vikkula M. Germline Mutations in RASA1 Are Not Found in Patients with 
Klippel-Trenaunay Syndrome or Capillary Malformation with Limb Overgrowth. Mol 
Syndromol. 2013 Apr;4(4):173-8 
8. Bayrak-Toydemir P., Stevenson D. RASA1-Related Disorders. 2011 Feb 22 [Updated 2016 
Oct 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. 
Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK52764/ 
9. Sung HM, Chung HY, Lee SJ, et al. Clinical Experience of the Klippel–Trenaunay 
Syndrome. Arch Plast Surg. 2015;42(5):552-8. 
10. Eerola I, Boon LM, Mulliken JB, et al. Capillary Malformation–Arteriovenous 
Malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum 
Genet. 2003;73(6):1240-9. 
11. Meirer R, Huemer GM, Shafighi M, Kamelger FS, Hussl H, Piza-Katzer H. Sciatic nerve 
enlargement in the Klippel- Tr_enaunay Weber syndrome. Br J Plast Surg 2005;58:565e8 
997 
 
12. O’Connor PS, Smith JL. Optic nerve variant in the Klippel- Tr_enaunay-Weber 
syndrome. Ann Ophthalmol 1978;10: 131e4. 
13. Yildizdas  ¸ D, Antmen B, Bayram I, Yapicio_glu H. Klippel- Tr_enaunay-Weber 
syndrome with hydronephrosis and vesicoureteral reflux: an unusual association. Turk J 
Pediatr 2002;44:180e2. 
14. Duque JM, Mu~noz Navas M, Bet_es MT, S_ubtil JC, Ang_os R. Colonic involvement in 
the Klippel-Tr_enaunay-Weber syndrome. Rev Esp Enferm Dig 2000;92:44e5. 
15. Alpay F, K€urekc  ¸i AE, G€unes l¸i S, G€okc¸ay E. Klippel-Tr_enaunay- Weber syndrome 
with hemimegalencephaly. Report of a case. Turk J Pediatr 1996;38:277e80. 
16. Bhat L, Bisht S, Khanijo K. Klippel-Trenaunay-Weber Syndrome with Kasabach-Merritt 
Coagulopathy and Hydronephrosis. Indian Pediatr. 2015;52(11):987-8. 
17. S. Ziyeh, J. Spreer, J. Rössler, R. Strecker, A. Hochmuth, M. Schumacher,  J. Klisch J. 
Spreer J. Rössler R. Strecker A. Hochmuth M. Schumacher J. Klisch Parkes Weber or 
Klippel-Trenaunay syndrome? Non-invasive diagnosis with MR projection angiography. 
EurRadiol (2004) 14:2025–2029 
18. Li Z-F, Li Q, Xu Y, Hong B, Huang Q-H, Liu J-M, Spinal arteriovenous malformation 
associated with Parkes Weber syndrome: Report of two cases and literature review, World 
Neurosurgery (2017) 
